Systemic therapy of advanced bronchioloalveolar cell carcinoma: Challenges and opportunities

Journal of Clinical Oncology

Volumn 23, Issue 14, 2005, Pages 3288-3293

  Miller, Vincent A ^a   Hirsch, Fred R ^a   Johnson, David H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CG 8123; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; GENE MUTATION; HUMAN; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; RETROSPECTIVE STUDY; REVIEW; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; LUNG TUMOR; PATHOLOGY;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS;

EID: 19844362716     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.19.240     Document Type: Review

References (42)

1. Travis WD, Colby TV, Corrin B, et al: Histological typing of lung and pleural tumors, 3rd Ed. Berlin, Springer Verlag, 1999
2. Ebright MI, Zakowski MF, Martin J, et al: Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 74: 1640-1646, 2002
3. Read WL, Page NC, Tierney RM, et al: The epidemiology of bronchioloalveolar carcinoma. Proc Am Soc Clin Oncol 21:317, 2002 (abstr 1267)
4. Barsky SH, Cameron R, Osann KE, et al: Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer 73:1163-1170, 1994
5. Furak J, Trojan I, Szoke T, et al: Bronchioloalveolar lung cancer: Occurrence, surgical treatment and survival. Eur J Cardiothorac Surg 23:818-823, 2003
6. Albain KS, Crowley JJ, LeBlanc M, et al: Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9:1618-1626, 1991
7. Kris MG, Cohen E, Gralla RJ: An analysis of 134 phase II trials in non-small cell lung cancer. 4th World Conference on Lung Cancer. Toronto, Canada, August 25-30, 1985, p 39
8. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
9. Breathnach OS, Ishibe N, Williams J, et al: Clinical features of patients with stage IIIB and IV bronchioloalveolar carcinoma of the lung. Cancer 86:1165-1173, 1999
10. Gralla RJ, Kalasiak A, Kris MG, et al: Bronchoalveolar carcinoma of the lung (BAC): Patient parameters and responsiveness to chemotherapy in patients with Stage III and IV disease. Lung Cancer 4:A63, 1988
11. West HL, Crowley JJ, Vance RB, et al: Advanced brocnhioloalveolar carcinoma: A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714). Ann Oncol: in press
12. Ranson M, Hammond LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 20:2240-2250, 2002
13. Herbst R, Maddox A-M, Rothenberg M, et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 20:3815-3825, 2002
14. Miller VA, Kris MG, Shah N, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22:1103-1109, 2004
15. Kris MG, Sandler A, Miller V, et al: Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar cacinoma (BAC). Proc Am Soc Clin Oncol 23:631S, 2004
16. West H, Franklin WA, Gumerlock PH, et al: Gefitinib (ZD1839) therapy for advanced bronchioioalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Proc Am Soc Clin Oncol 23:7014, 2004
17. Fukuoka M, Yano S, Giaccone G, et al: Multi-Institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003
18. Moody SE, Sarkisian CJ, Hahn KT, et al: Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2:451-461, 2002
19. Fisher GH, Wellen SL, Klimstra D, et al: Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15:3249-3262, 2001
20. Felsher DW, Bishop JM: Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4:199-207, 1999
21. Chin L, Tam A, Pomerantz J, et al: Essential role for oncogenic Ras in tumour maintenance. Nature 400:468-472, 1999
22. Weinstein I: Cancer. Addiction to oncogenes-The Achilles heal of cancer. Science 297:63-64, 2002
23. Druker BJ, Talpaz M, Resta D, et al: Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
24. Demetri G: Targeting c-kit mutations in solid tumors: Scientific rationale and novel therapeutic options. Semin Oncol 28:19-26, 2001
25. Cools J, DeAngelo DJ, Gotlib J, et al: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201-1214, 2003
26. Bardelli A, Parsons DW, Silliman N, et al: Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300:949, 2003
27. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
28. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
29. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
30. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al: Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798-3807, 2003
31. Slebos RJ, Hruban RH, Dalesio O, et al: Relationship between k-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 83:1024-1027, 1991
32. Gumerlock PH, Holland WS, Chen HL, et al: Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioloalveolar carcinoma patients treated with gefitinib. Proc Am Soc Clin Oncol 24: 2005
33. Hirsch FR, Varella-Garcia M, West H, et al: Increased EGFR gene copy number detected by FISH associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes. J Clin Oncol: submitted
34. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst: in press
35. Parra HS, Cavina R, Latteri F, et al: Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 91:208-212, 2004
36. Sirotnak FM, Zakowski MF, Miller VA, et al: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 ('Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885-4892, 2000
37. Franklin WA, Gumerlock PH, Crowley JC, et al: EGFR, HER2 and ERB-B pathway activation in bronchioloalveolar carcinoma analysis of SWOG 9417 and lung SPORE tissue samples. Proc Am Soc Clin Oncol 22:371, 2003 (abstr 2493)
38. Gandara DR, West H, Chansky K, et al: Bronchioloalveolar carcinoma: A model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res 10: 4205s-4209s, 2004
39. Carbone DP, Adak S, Schiller J, et al: Adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioalveolar cell lung carcinoma (BAC). Proc Am Soc Clin Oncol 22: 620, 2003 (abstr 2492)
40. Salgia R, Lynch T, Skarin A, et al: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 21: 624-630, 2003
41. Nemunaitis J, Sterman D, Jablons J, et al: Phase I/I I study of autologous GM-CSF gene-modified cancer vaccines in subjects with non-small cell lung cancer (NSCLC). International Conference on Gene Therapy, December 13-15, 2001, San Diego, CA
42. Stevenson JP, Nho CW, Johnson SW, et al: Effects of bortezomib (PS-341) on NF-kB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: A phase II/pharmacodynamic trial. Proc Am Soc Clin Oncol 23: 649, 2004